| 36 |
Oral Abstracts (Session 5 of 5)
|
Moderator: David Keast, MSc, MD, CCFP, FCFP (Presentation 36.4) Immune response to an extracellular matrix tissue graft used to treat chronic venous ulcers Jason P. Hodde, MS, ATC/L; Michael C. Hiles, PhD, Cook Biotech Incorporated, West Lafayette, Ind; Nicholas Sillings, BS; Dennis W. Metzger, PhD, Center for Immunology and Microbial Disease, Albany Medical College, Albany, NY Abstract: Biomaterials derived from animal tissues are effective in healing chronic wounds but may contain proteins that can activate the human immune system. The human immune response to SIS wound matrix*, an acellular biomaterial derived from pigs, was investigated as part of a randomized clinical trial enrolling 120 patients. The trial evaluated the effectiveness of SIS wound matrix plus compression versus compression alone for healing chronic venous ulcers by 12 weeks. In a subset of 12 patients randomized to the SIS group, serum and wound exudate were collected at baseline and at weekly intervals. Serum was analyzed for antibodies (total immunoglobins) to the biomaterial, and wound exudates were analyzed for changes in TGF-b. After 12 weeks, 55% (34/62) of wounds treated with SIS plus compression were healed versus 34% (20/58) of wounds treated with compression alone (p=0.0196). In the subset population, 6 of 12 wounds healed. None of the 12 patients formed an antibody response to SIS. Healing wounds had increased levels of TGF-b as compared to nonhealing wounds. These data show that SIS plus compression is more effective in healing chronic venous ulcers than compression alone and does not lead to immune system recognition when used to stimulate wound healing. * Oasis Wound Matrix, Healthpoint, Fort Worth, Tex References 1. Brown-Etris M, Cutshall WD, Hiles MC. A new biomaterial derived from small intestine submucosa and developed into a wound matrix device. WOUNDS. 2002;14:150–166. 2. Carson SN, Travis E, Overall K, Lee-Jahshan S. Using becaplermin gel with collagen products to potentiate healing in chronic leg wounds. WOUNDS. 2003;15:339–345. 3. Demling RH, Niezgoda JA, Haraway GD, Mostow EN. Small intestinal submucosa wound matrix and full-thickness venous ulcers: preliminary results. WOUNDS. 2004;16:18–22. 4. Hodde JP, Ernst DMJ, Hiles MC. An investigation of long-term bioactivity of endogenous growth factor in OASIS Wound Matrix. J Wound Care. 2005;14(1):23–25. 5. Hodde JP, Hiles MC. Bioactive FGF-2 in sterilized extracellular matrix. WOUNDS. 2001;13(5):195–201. |
|